Alto Neuroscience Inc (NYSE: ANRO) is 9.69% higher on its value in year-to-date trading and has touched a low of $3.56 and a high of $24.00 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ANRO stock was last observed hovering at around $4.43 in the last trading session, with the day’s gains setting it 0.21%.
Currently trading at $4.64, the stock is 8.96% and 10.16% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.2 million and changing 4.74% at the moment leaves the stock -54.12% off its SMA200. ANRO registered a loss of -69.81% in past 6-months. The firm has a 50-day simple moving average (SMA 50) of $4.212 and a 200-day simple moving average (SMA200) of $10.11275.
The stock witnessed a 23.73% gain in the last 1 month and extending the period to 3 months gives it a -67.89%, and is 6.67% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.51% over the week and 7.52% over the month.
Alto Neuroscience Inc (ANRO) has around 63 employees, a market worth around $125.14M and $0.00M in sales. Distance from 52-week low is 30.34% and -80.67% from its 52-week high. The company has generated returns on investments over the last 12 months (-32.35%).
The EPS is expected to grow by 73.42% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
Alto Neuroscience Inc (ANRO) Top Institutional Holders
The shares outstanding are 26.97M, and float is at 22.89M with Short Float at 17.36%.
Alto Neuroscience Inc (ANRO) Insider Activity
The most recent transaction is an insider purchase by Savitz Adam, the company’s CHIEF MEDICAL OFFICER. SEC filings show that Savitz Adam bought 12,069 shares of the company’s common stock on Jul 09 ’24 at a price of $12.60 per share for a total of $0.15 million. Following the purchase, the insider now owns 36920.0 shares.
Alto Neuroscience Inc disclosed in a document filed with the SEC on Jul 10 ’24 that Savitz Adam (CHIEF MEDICAL OFFICER) bought a total of 2,931 shares of the company’s common stock. The trade occurred on Jul 10 ’24 and was made at $13.22 per share for $38748.0. Following the transaction, the insider now directly holds 39851.0 shares of the ANRO stock.
Still, SEC filings show that on Mar 28 ’24, Smith Nicholas Conrad (CHIEF FINANCIAL OFFICER) acquired 6,150 shares at an average price of $16.36 for $0.1 million. The insider now directly holds 26,866 shares of Alto Neuroscience Inc (ANRO).
